Does it Affect Platelet Quality?

The therapeutic efficacy and safety of platelets treated with the INTERCEPT™ Blood System has been demonstrated in 10 randomised clinical trials and through different haemovigilance programmes evaluating >390.000 platelet transfusions.¹

Safety in routine use has also been demonstrated in different patient populations such as cardiovascular patients, haematology/oncology patients, and neonatal and paediatric patients.

In order to be approved for routine use in countries including France, Germany, Switzerland and the US, additional safety and efficacy data was submitted to the local regulatory agencies. INTERCEPT is currently the only pathogen inactivation/reduction method for platelets that has received approval from German, French, Swiss and US authorities for routine use.

Source:

1.L. Corash, R.J. Benjamin, The role of hemovigilance and postmarketing studies when introducing innovation into transfusion medicine practice: the amotosalen-ultraviolet A pathogen reduction treatment model. Transfusion 2016,56,S29-S38